SCHEMBL2474504

SCHEMBL2474504

C=CCC(N)c1ccccc1-c1ccc(C)c(F)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 7/20 0.38
FEN1 P39748 7/20 0.38
PDCD1LG2 Q9BQ51 2/20 0.36
CD274 Q9NZQ7 2/20 0.36
AKR1C3 P42330 3/20 0.35
AKR1C2 P52895 3/20 0.35
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
AKR1B10 O60218 2/20 0.33
AKR1C4 P17516 2/20 0.33
AKR1C1 Q04828 2/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
DPP4 P27487 1/20 0.32
CHRM3 P20309 1/20 0.31
HTR7 P34969 1/20 0.31
CTSA P10619 1/20 0.31
REN P00797 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2476054 0.84 FEN1 (0.40) ALOX5APFEN1AKR1C3AKR1C2AKR1C4
SCHEMBL2477561 0.84 PDCD1LG2 (0.38) ALOX5APFEN1PDCD1LG2CD274DPP4
SCHEMBL2471466 0.80 PTGS2 (0.38) PDCD1LG2CD274MAPTHTR7
SCHEMBL7438146 0.80 PDCD1LG2 (0.40) PDCD1LG2CD274TP53MAPT
SCHEMBL2474135 0.80 PDCD1LG2 (0.40) PDCD1LG2CD274TP53MAPT
SCHEMBL2473732 0.80 PDCD1LG2 (0.36) PDCD1LG2CD274CTSA
SCHEMBL2480866 0.78 HDAC4 (0.42) PDCD1LG2CD274
SCHEMBL2474346 0.77 PDCD1LG2 (0.36) ALOX5APFEN1PDCD1LG2CD274
SCHEMBL2477497 0.77 PDCD1LG2 (0.39) PDCD1LG2CD274MAPT
SCHEMBL19332982 0.76 CYP2C19 (0.38) PDCD1LG2CD274MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2159216-B1 3-BUTENYL-1-AMINE DERIVATIVES AND THEIR USE AS Ih MODULORS FOR THE TREATMENT OF PSYCHIATIRC DISORDERS ORGANON NV (NL) 2011-10-12 EP disclosed
EP-2159216-A1 Ih - Modulators N.V. Organon (NL) 2010-03-03 EP disclosed
US-20040229910-A1 Therapeutic compounds N.V. ORGANON (NL) 2004-11-18 US disclosed
US-20020037885-A1 Therapeutic compounds DIJCKS FREDERICUS ANTONIUS (NL) 2002-03-28 US disclosed
US-6313139-B1 ADMINISTERING BENZYLAMINE DERIVATIVE FOR THERAPY OF PSYCHIATRIC DISORDER IN MAMMALS AKZO NOBEL N. V. (NL) 2001-11-06 US disclosed
EP-1035843-A2 I h?-MODULATORS Akzo Nobel N.V. (NL) 2000-09-20 EP disclosed
US-6080773-A USEFUL FOR TREATMENT OF DEPRESSION, ANXIETY OR PSYCHOSIS AKZO NOBEL, N.V. (NL) 2000-06-27 US disclosed
WO-1999018941-A2 Ih-MODULATORS AKZO NOBEL N.V. (NL) 1999-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229910-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ALOX5AP 1404/4885FEN1 4625/4885PDCD1LG2 3624/4885
US-20020037885-A1 Therapeutic compounds BDNF, PNMT, SLC18A2 ALOX5AP 1404/4885FEN1 4625/4885PDCD1LG2 3624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.